Live at the SIIA 2022 Engage Conference, we have our special guest Jeff Kelly, President at Buckingham Self-Funded Solutions. During this visit with host, Sally Pace, Jeff explains how gene therapy crosses over into stop loss. "Gene therapy translating into stop loss is the equivalent of profitability versus loss. As a stop loss carrier retaining a set threshold of risk and these gene therapy drugs coming out with the names that we have all heard, these million dollar price tags and such. I mean these are almost automatic claims to a stop so that these gene therapy drugs and the advanced biosimilar companies bringing in these cancer therapies and J codes, G codes, and every other code that we're about to become aware of. So bringing in cost contain measures stop-loss carriers are already acutely aware of this and they're already putting together solutions. So gene therapy is unfortunately here to stay. It will be evolving throughout the future." Learn more in this episode of The Granite List Live.
How to Identify High-Value Family-Forming Benefits
Navigating the GLP-1 Wave: Strategies for 2024
Collaboration to Overcome Challenges
Bringing Savings to Plan Members with Reference Based Pricing
Using Data to Understand Your Population's Needs
Total Health with Advanced Primary Care
Avoiding Adverse Side Effects
Utilizing GLP-1 Drugs as a Tool - Not the Solution
Not Surgery - Recovery Using the Body's Own Cells
An International Pharmacy
MasterClass for Juniors
The Importance of Family-Forming Benefits
A Captive as a Shock Absorber
It All Starts With a Budget
Gag Clause Attestation
City-Builders of Direct Primary Care
A Partnership Made in Total Worker Health Heaven
Surgeons of Excellence
Providing the Missing Human Element
Introducing FoodMed Certified
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
Aligned Money Show
Gorse Culture PODcast : The H.R. Detective Agency!
HCI Leadership Revolution
The Ramsey Show
Planet Money